1700019O17Rik Inhibitors
Chemical inhibitors of 1700019O17Rik employ various methods to modulate the activity of this protein. Staurosporine, a well-known protein kinase inhibitor, can impede the activity of 1700019O17Rik by obstructing the phosphorylation processes that are essential for its activation. Similarly, wortmannin and LY294002, both inhibitors of phosphoinositide 3-kinases (PI3K), can prevent the PI3K-mediated signaling cascades that are necessary for the functioning of 1700019O17Rik. The inhibition of PI3K by these chemicals leads to a reduction in the downstream effects that contribute to the protein's role in cellular pathways. Rapamycin, targeting mTOR kinase, a component of the mTOR signaling pathway, can also suppress the activity of 1700019O17Rik by inhibiting the pathway that facilitates its activation.
Other chemical inhibitors operate by targeting different kinases that influence the activity of 1700019O17Rik. Triciribine, an AKT inhibitor, can reduce the activity of 1700019O17Rik by hindering the AKT pathway, which is implicated in cell survival and proliferation. SP600125 works through the inhibition of c-Jun N-terminal kinase (JNK), potentially preventing the activation of 1700019O17Rik if it is a part of the JNK signaling cascade. Inhibition of the JAK-STAT pathway by lestaurtinib, which targets JAK2 kinase, can suppress the activity of proteins regulated by this pathway, including 1700019O17Rik. Similarly, SB203580 and PD98059, which target p38 MAP kinase and MEK respectively, can inhibit the MAPK signaling pathway and consequently the activity of 1700019O17Rik. U0126, another MEK inhibitor, functions in a comparable manner to PD98059, to suppress MAPK pathway signaling. Finally, PP2 and dasatinib, which inhibit Src family kinases and BCR-ABL kinase respectively, can decrease the activity of downstream signaling proteins such as 1700019O17Rik by blocking the kinases that regulate their activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting these kinases, staurosporine can lead to the inhibition of 1700019O17Rik by blocking the phosphorylation events necessary for its activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K). Since 1700019O17Rik is involved in pathways downstream of PI3K, wortmannin would inhibit 1700019O17Rik activity by preventing PI3K-mediated signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, functioning similarly to wortmannin. It would inhibit 1700019O17Rik by halting the PI3K pathway and its downstream effects, which include the activation of proteins such as 1700019O17Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in the mTOR signaling pathway. Since 1700019O17Rik operates downstream of mTOR, rapamycin would inhibit the signaling that activates 1700019O17Rik. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an inhibitor of AKT, which is involved in cell survival and proliferation pathways. Inhibition of AKT leads to a reduction in 1700019O17Rik activity if 1700019O17Rik is regulated by AKT signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which could be part of the signaling cascade that activates 1700019O17Rik. By inhibiting JNK, SP600125 would prevent the activation of 1700019O17Rik. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Lestaurtinib is an inhibitor of the JAK2 kinase. By inhibiting JAK2, lestaurtinib prevents the activation of the JAK-STAT signaling pathway, which in turn inhibits the activity of proteins like 1700019O17Rik that are regulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in the MAPK signaling pathway. Inhibition of p38 MAPK by SB203580 would lead to the inhibition of downstream proteins such as 1700019O17Rik that are part of the MAPK pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which works upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 prevents the subsequent activation of ERK and its downstream targets, including 1700019O17Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also inhibits MEK, similar to PD98059, resulting in the inhibition of the MAPK pathway and the activity of downstream proteins such as 1700019O17Rik. | ||||||